Based on the data from the monarchE clinical trial, the FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of hormone receptor-positive/HER2-negative, node positive, early breast cancer with a Ki-67 score ≥20%. Here, NR4A1 is linked to breast carcinoma.